Bayer
BAYN.DE Large CapHealthcare · Drug Manufacturers - General
Updated: Jul 5, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health
Bayer Stock at a Glance
Bayer (BAYN.DE) is currently trading at €53.36 with a market capitalization of $52.4B. The 52-week range spans from €24.80 to €53.92; the current price is 1% below the yearly high. Year-over-year revenue growth stands at -2.4%.
💰 Dividend
Bayer pays an annual dividend of €0.11 per share, representing a yield of 0.21%. The payout ratio stands at 163.27%. The elevated payout ratio reflects a mature dividend policy.
📊 Analyst Rating
18 analysts rate Bayer (BAYN.DE) on consensus: Buy. The average price target is €52.47, implying -1.66% from the current price. Analyst price targets range from €40.50 to €65.00.
Bayer: The Investment Case in Detail
Bayer (BAYN.DE) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Earnings growth of 112.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 59.92% gross margin and 26.32% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat.
The Bear Case
Revenue is contracting at -2.4% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Valuation in Context
At a PEG of 4.65, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 8.35x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
What to Watch Next
- The share is trading at 98.1% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 59.92% — indicates pricing power
- Analyst consensus: Buy
- Positive free cash flow
- –Revenue shrinking (-2.4% YoY)
- –Currently unprofitable
- –Price near 52-week high — limited upside cushion
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Bayer 2026: Pharma Pipeline, Glyphosate Endgame, and Bill Anderson's Reform Shock
The Real Story
Bayer remains one of the most polarizing stocks in the DAX in 2026. CEO Bill Anderson, in post since June 2023, has run the group in perpetual reform mode. The 2025 launch of Dynamic Shared Ownership (DSO) — the dissolution of classical middle management — was supposed to cut 5,500 roles, but landed only partly. As of Q1/2026: revenue €14.4B (-2.8% YoY), core EPS €2.18 (vs. €2.02 consensus), free cash flow €1.1B (a sharp improvement vs. -€1.3B in Q1/2025).
The market has two dominant 2026 worries: (1) Glyphosate litigation: the US plaintiff pipeline still has roughly 67,000 open cases, with cumulative settlement payments at $11.2B through Q1/2026. Anderson announced a ‘single-event settlement path’ in February 2026 — a federal-level resolution intended to bury the risk for good. (2) Aspirin Plus C recalls in China cost the consumer-health segment €800M of reputational damage, which the margin recovery in Crop Science has not offset.
On the pharma pipeline, Bayer holds two real 2026 hopes: Asundexian (factor-XIa inhibitor, stroke prevention) is in Phase 3 with a mid-2027 approval pathway — peak sales estimates run €5–7B. And Acoramidis (ATTR cardiomyopathy, in-licensed from BridgeBio) starts full European commercialization in 2026.
What Smart Money Thinks
Bayer is a textbook ‘activist battleground’ in 2026: Bluebell Capital still holds 0.9% and has been pushing for a break-up into Pharma, Crop Science, and Consumer Health since 2023. Inclusive Capital Partners (Jeff Ubben) opened a similar position in Q4/2025. Anderson responded in March 2026 with a ‘strategic review’ announcement — final word in Q4 2026.
Traditional long side: Allianz Global Investors (the home-market anchor) is steady at 4.1%, Vanguard at 3.0%, Norges Bank at 2.8%. Notable: Capital Group dropped below 1% in 2026 for the first time since 2019 — the loss of an important US-mandate sponsor.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
If Anderson lands a federal settlement in Q4 2026 (J&J talc-trust style), the glyphosate multiple discount of roughly €4B reserve plus €15–20B implicit risk premium should shrink materially — the market would re-rate by ~30%.
The factor-XIa inhibitor shows a clearly better bleeding profile vs. Xarelto/Eliquis in Phase 3 data so far. A successful 2027 approval in stroke prevention could give Bayer Pharma its first true >€5B blockbuster since Xarelto.
Bayer's dividend collapsed from €2.40 to €0.11 in 2024 — a brutal cut for the German retail base. Anderson has signaled publicly that restoration to a ‘reasonable level’ will follow the litigation endgame — the market expects €0.80–1.20 in 2027.
📉 The 3 Real Bear Points
A federal single-event settlement along the J&J talc template could create a $30–50B balance-sheet impact — even if it removes the risk premium, it would push Bayer to a pro-forma net debt/EBITDA of 5–6×.
The originally announced ‘hierarchy dissolution’ did not progress at the planned pace in 2025. Anderson admitted in February 2026 that only 60% of target headcount reductions are implemented. Further delays erode the margin story credibility.
Patents on XtendiMax and Roundup-Ready Soy expire in the US in 2027. Chinese generics producers (Hubei Sanonda, Yangnong) entered the US professional channel with off-patent glyphosate in 2025 and have already eroded pricing power.
Valuation in Context
Bayer trades at 5.8× 2026 P/E — one of the lowest valuations in the entire DAX. On 2026 core EPS of €4.80, the earnings yield is 17%. SOTP valuation puts the three segments at: Pharma €38–45B, Crop Science €22–30B, Consumer Health €10–13B. Total €70–88B EV minus €35B net debt = €35–53B equity, i.e. €36–54 per share. Current price (~€28) sits well below SOTP — a 22–48% holding discount. The stock is a high-conviction special-situations play; the dominant question is litigation, not operations.
🗓️ Next 3 Catalyst Dates
- Q3 2026: Expected Asundexian Phase 3 topline data (OCEANIC-AF and OCEANIC-STROKE). Positive readouts could trigger a 15–20% single-day rally.
- Q4 2026: Anderson's strategic review verdict on group break-up. The market will price between ‘break-up coming’ and ‘structural optimization only’.
- H1 2027: Possible federal glyphosate settlement announcement following the J&J talc template. Would be the definitive de-risking event since the 2018 Monsanto deal.
💬 Daniel's Take
Bayer is not for weak nerves — the stock can swing 8% in a day on a single litigation headline. But the fundamental asymmetry in 2026 finally favors the bull case: 30%+ SOTP discount, Asundexian optionality, mounting reform pressure on Anderson. I hold 2.5% portfolio weight, built over 18 months via DCA, and consciously accept the high volatility. If you want pharma beta without the Bayer-specific tail, prefer Novo Nordisk or Roche.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Bayer?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news